Instituto Tecnológico de Oftalmología, Hospital Nuestra Señora de la Esperanza, Av de las Burgas 2, Santiago de Compostela, Spain.
Br J Ophthalmol. 2011 Mar;95(3):391-5. doi: 10.1136/bjo.2009.177287. Epub 2010 Aug 7.
To report the early development of epiretinal membranes (ERM) in eyes with retinal vein occlusions (RVO) treated with intravitreal bevacizumab and to describe possible mechanisms that may be involved in the growth and contraction of these lesions.
Retrospective and interventional study that included 25 eyes of 25 patients with RVO (16 eyes with central retinal vein occlusion and nine eyes with branch retinal vein occlusion). After an initial 2.5mg/0.1ml intravitreal bevacizumab injection all patients were followed-up every 6 weeks. Re-treatments were based on visual acuity and optical coherence tomography findings. Results Twenty-five eyes were treated with bevacizumab and followed for 8.3 (range 4.5-13.5) months. Four eyes developed an ERM within 6-7weeks after the administration of bevacizumab. ERM was not associated with further deterioration of visual acuity or metamorphopsia in these patients. A rebound of macular oedema was observed in one patient with ERM and in two other patients. No other side effects were observed.
Intravitreal bevacizumab may be associated with an early growth of ERM in eyes with RVO, although a causative relationship cannot be established. Future randomised clinical trials are necessary to determine the efficacy and safety profile of this novel therapy.
报告视网膜静脉阻塞（RVO）患者接受玻璃体内贝伐单抗治疗后早期发生的视网膜内膜（ERM）的发展情况，并描述可能涉及这些病变生长和收缩的可能机制。
这是一项回顾性和干预性研究，共纳入 25 只眼 25 例 RVO 患者（16 只眼为中央视网膜静脉阻塞，9 只眼为分支视网膜静脉阻塞）。所有患者在初次接受 2.5mg/0.1ml 玻璃体内贝伐单抗注射后，每 6 周进行一次随访。根据视力和光学相干断层扫描结果进行再治疗。
25 只眼接受贝伐单抗治疗并随访 8.3 个月（4.5-13.5 个月）。在贝伐单抗给药后 6-7 周内，有 4 只眼发生了 ERM。在这些患者中，ERM 并未导致视力或变形进一步恶化。在 1 例伴有 ERM 的患者和另外 2 例患者中观察到黄斑水肿的反弹。未观察到其他不良反应。
尽管无法确定因果关系，但玻璃体内贝伐单抗可能与 RVO 患者的 ERM 早期生长有关。未来需要进行随机临床试验以确定这种新疗法的疗效和安全性。
